Selected article for: "lung injury and overall survival"

Author: Jun Wu; Dingyun Song; Zhongwen Li; Baojie Guo; Yani Xiao; Wenjing Liu; Lingmin Liang; Chunjing Feng; Tingting Gao; Zai Wang; Jianyan Wen; Shengnan Yang; Peipei Liu; Lei Wang; Yukai Wang; Liang Peng; Guihai Feng; Shiqiang Huang; Glyn Nigel Stacey; Wei Li; Yan Huo; Ronghua Jin; Qi Zhou; Liu Wang; Baoyang Hu; Huaping Dai; Jie Hao
Title: Immunity-and-Matrix-Regulatory Cells Derived from Human Embryonic Stem Cells Safely and Effectively Treat Mouse Lung Injury and Fibrosis
  • Document date: 2020_4_16
  • ID: 8dpla6jt_77
    Snippet: Pirfenidone (PFD) is an FDA-approved drug for the treatment of idiopathic pulmonary fibrosis. It works 517 by reducing lung fibrosis through downregulating the production of growth factors and procollagens I 518 and II. To evaluate the efficacy of IMRC treatment, we compared it side-by-side with UCMSCs and PFD 519 treatments of BLM-injured mice (Fig. 6J) . Our results showed that IMRC treatment led to an improved 520 amelioration of the weight re.....
    Document: Pirfenidone (PFD) is an FDA-approved drug for the treatment of idiopathic pulmonary fibrosis. It works 517 by reducing lung fibrosis through downregulating the production of growth factors and procollagens I 518 and II. To evaluate the efficacy of IMRC treatment, we compared it side-by-side with UCMSCs and PFD 519 treatments of BLM-injured mice (Fig. 6J) . Our results showed that IMRC treatment led to an improved 520 amelioration of the weight reduction after BLM-induced lung injury, compared to UCMSCs or PFD 521 treatments (Fig. 6K) . Kaplan-Meier survival curves indicated that the IMRC treatments also resulted in 522 the highest overall survival rates compared to UCMSCs or PFD treatments ( Fig. 6L ; BLM group 39.02%, 523

    Search related documents:
    Co phrase search for related documents